Free tool
FAERS Monitor: Xcopri
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212839 or its brand name (Xcopri, Cenobamate). Reports on generic versions are filed under their own applications.
Reports
8,531
Serious
3,375
40% of reports
Hospitalization
1,798
Death reported
208
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure2,543
- product dose omission issue1,880
- fatigue845
- somnolence823
- off label use691
- dizziness668
- product use issue608
- fall470
- headache391
- wrong technique in product usage process382
- drug ineffective380
- drug interaction364
- feeling abnormal302
- gait disturbance289
- balance disorder263
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 5 |
| 2020 | 84 |
| 2021 | 1,679 |
| 2022 | 612 |
| 2023 | 558 |
| 2024 | 1,527 |
| 2025 | 2,057 |
| 2026 | 2,009 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,628 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 2,543 | 55.5 | 53.7 | 133,730 |
| product dose omission issueSignal | 1,880 | 15.9 | 15.2 | 26,356 |
| somnolenceSignal | 823 | 10.1 | 9.5 | 6,788 |
| product use issueSignal | 608 | 8.0 | 7.4 | 3,738 |
| balance disorderSignal | 263 | 7.5 | 6.7 | 1,482 |
| drug interactionSignal | 364 | 5.7 | 5.1 | 1,402 |
| wrong technique in product usage processSignal | 382 | 4.7 | 4.2 | 1,101 |
| gait disturbanceSignal | 289 | 3.7 | 3.3 | 578 |
| fallSignal | 470 | 3.5 | 3.2 | 843 |
| dizzinessSignal | 668 | 3.3 | 3.1 | 1,096 |
| feeling abnormalSignal | 302 | 3.1 | 2.8 | 435 |
| fatigueSignal | 845 | 2.7 | 2.5 | 920 |
| off label use | 691 | 1.9 | 1.8 | 331 |
| headache | 391 | 1.5 | 1.4 | 75 |
| drug ineffective | 380 | 0.7 | 0.6 | 47 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.